Effect of F2695 on Functional Recovery After Ischemic Stroke

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pierre Fabre Medicament

Criteria

Inclusion Criteria:

• Male or female patient, 18 to 80 years of age

• Confirmed acute ischemic stroke within the past 2 - 10 days

• Unilateral motor deficit,

• National Institutes of Health stroke scale (NIHSS) motor score >= 5

• Modified Rankin Scale (mRS) of 4 or 5

• Able and willing to comply with the site rehabilitation program requirements

Exclusion Criteria:

• Aphasia

• Severe post-stroke condition

• Active depressive episode

• Intra-cerebral hemorrhage

• Use of anti-depressant drugs

• Cardiac rhythm disorder

• Uncontrolled arterial hypertension

• Other severe acute or chronic medical or psychiatric condition.